Compass Pathways completes FDA application for COMP360
On November 9, Compass Pathways said it had finished filing an NDA with the U.S. FDA for COMP360, its investigational psilocybin treatment for treatment-resistant depression. The application draws on two Phase 3 studies and one Phase 2b study, each of which met its primary endpoint and together enrolled more than 1,000 people. The company is preparing for a possible H12027 launch, but commercialization depends on FDA clearance.
Why it matters
The filing moves COMP360 into the FDA review process, while approval remains a prerequisite for sales. Compass Pathways expects launch preparation to support a possible H12027 introduction, and Jefferies forecasts that an expedited review could allow approval as early as December or January.
Key facts
- 1Compass Pathways completed an NDA filing with the U.S. FDA for COMP360 in treatment-resistant depression. finanznachrichten.de
- 2The supporting clinical package consists of two Phase 3 trials and one Phase 2b study, with each study meeting its primary endpoint and the combined programme involving more than 1,000 participants. finanznachrichten.de
- 3The company says its commercial infrastructure is ready for a potential H12027 launch, subject to FDA approval. finanznachrichten.de
- 4Jefferies estimates that the FDA review could take one to two months using a Commissioner's National Priority Voucher. finance.yahoo.com
- 5Jefferies projects a possible US commercial launch during the first half of 2027 and 2027 revenue of $31 million. finance.yahoo.com
Open questions
- FDA approval, its timing, labeling, and any required safety controls remain undecided.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.